Dilated cardiomyopathy is a complex multigene-regulated cardiac dysfunction with a complex pathogenesis and no specific therapeutic approach. Ace Therapeutics aims to provide researchers with research model development, pathogenesis studies and novel therapy discovery services for dilated cardiomyopathy.
Dilated cardiomyopathy is a group of cardiac dysfunctions characterized by impaired myocardial contractile function due to ventricular dilatation, which may lead to arrhythmias, heart failure and even sudden cardiac death. The etiology of dilated cardiomyopathy is complex and varied, and the pathogenic mechanism is still unclear. Current research on the pathogenesis of dilated cardiomyopathy mainly focuses on the search for disease-causing gene mutations and their impact on the damage to cell structure and function. Therefore, in-depth investigation of the pathogenic mechanism of dilated cardiomyopathy and searching for appropriate therapeutic targets is the most important task in the current research field.
Fig. 1 Genetic causes of dilated cardiomyopathy. (Schultheiss HP, et al., 2019)
Because dilated cardiomyopathy has diverse symptoms and is prone to complications, its drug therapy strategy is focused on improving symptoms and preventing complications. Currently, nucleic acid-based therapy and cell-based therapy strategies show great potential for drug development in dilated cardiomyopathy, and are expected to treat dilated cardiomyopathy from the perspective of pathogenesis.
| Drug Name | Drug Targets | Original Organization | Drug Phase |
|---|---|---|---|
| ARRY-797 | p38 MAPK | Array BioPharma, Inc. | Phase 3 |
| Talfirastide | Mas receptor | Tarix Orphan LLC | Phase 3 |
| Danicamtiv | Cardiac myosin | MyoKardia, Inc. | Phase 2 |
| Ifetroban | TBXA2R | Bristol Myers Squibb Co. | Phase 2 |
| SRD-001 | SERCA2 | Sardocor Corp. | Phase 1 |
| REN-001 | BAG3 | Renovacor, Inc. | IND |
| STM-01 | / | Secretome Therapeutics, Inc. | Preclinical |
Ace Therapeutics is committed to supporting basic research and development of novel therapeutic approaches for dilated cardiomyopathy by providing outsourced research services for disease model development and related research technology platforms.
Research Models
Basic Research
Drug Development
Animal models are the most commonly used disease research models to study dilated cardiomyopathy. We are able to provide customized transgenic and gene-edited animal models to facilitate the study of the pathogenesis of dilated cardiomyopathy and the development of novel drugs.
Transgenic Animal Model Development Services
We can provide animal models such as mice, rats, zebrafish, rabbits, dogs, and pigs, to carry out customized transgenic or knockout animal model construction services for our clients, including but not limited to the following genes:
Genetically Engineered Mouse Models
We offer the following high quality genetically engineered mice for dilated cardiomyopathy research.
In recent years, research on dilated cardiomyopathy has focused on the investigation of its pathogenesis. With our professional multi-omics research and pathology imaging technology platform, we are able to provide our clients with dilated cardiomyopathy pathogenesis research, experimental animal pathology diagnosis and the impact of auxiliary examination services.
Pathogenesis Research Services
Dilated cardiomyopathy is regulated by multiple genes, and its specific pathogenic mechanism has long been a research challenge. We are able to provide our clients with specialized research services according to their research needs.
Pathology and Imaging Services
For animal research of dilated cardiomyopathy, we can provide researchers with pathology and imaging services that enable intuitive model validation and efficacy assessment, including but not limited to:
We can provide research and development services for dilated cardiomyopathy drug therapies, including but not limited to the following drug types and targets:
R&D Services by Drug Type
R&D Services by Target
Ace Therapeutics has been involved in cardiovascular disease research for many years. We aim to provide our clients with animal model development, pathogenesis studies, and novel therapies discovery services for dilated cardiomyopathy. If you are interested in our research services for dilated cardiomyopathy, please don't hesitate to contact us.
Ace Therapeutics offers comprehensive solutions and R&D services to researchers worldwide to advance the field of cardiovascular diseases.
We do not provide medical care for patients.
Copyright © Ace Therapeutics. All rights reserved.